Cynosure Beats on Both Top and Bottom Lines

Cynosure (Nasdaq: CYNO  ) reported earnings on Feb. 12. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Cynosure beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share grew significantly.

Margins grew across the board.

Revenue details
Cynosure booked revenue of $42.7 million. The three analysts polled by S&P Capital IQ foresaw revenue of $41.0 million on the same basis. GAAP reported sales were 25% higher than the prior-year quarter's $34.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.27. The four earnings estimates compiled by S&P Capital IQ anticipated $0.23 per share. GAAP EPS of $0.27 for Q4 were 200% higher than the prior-year quarter's $0.09 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 58.1%, 300 basis points better than the prior-year quarter. Operating margin was 9.9%, 690 basis points better than the prior-year quarter. Net margin was 9.5%, 630 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $39.8 million. On the bottom line, the average EPS estimate is $0.17.

Next year's average estimate for revenue is $176.6 million. The average EPS estimate is $0.85.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 369 members out of 384 rating the stock outperform, and 15 members rating it underperform. Among 91 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 84 give Cynosure a green thumbs-up, and seven give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cynosure is outperform, with an average price target of $34.00.

Is Cynosure the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

• Add Cynosure to My Watchlist.